Nevertheless, the impact of IDO expression in the presence of tumor-infiltrating lymphocytes (TILs) and other immunoreactive inflammatory cells as macrophages/microglia or dendritic cells for the responsiveness to cancer immunotherapy is still elusive. The gene discussed is IDO1; the disease is cancer.